LGM
CAI

Lykos Global Management’s Caris Life Sciences CAI Stock Holding History

Lykos Global Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$270K – 20
2025
Q4 		$270K Buy
+10,000
New +$282K 0.19% 35

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Lykos Global Management's CAI Position: Q1 2026 in Review

Lykos Global Management sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 10,000 shares — an estimated $270K sold.

Lykos Global Management first reported a position in CAI in Q4 2025 and held it in 1 quarter. The position peaked at $270K in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Lykos Global Management reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Lykos Global Management sold 10,000 Caris Life Sciences shares in Q1 2026, an estimated $270K.
  • Lykos Global Management first reported a position in Caris Life Sciences in Q4 2025 and held it in 1 quarter.
  • Lykos Global Management's Caris Life Sciences position peaked at $270K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Lykos Global Management's 13F filing for Q1 2026, filed 15 May 2026.